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Purpose: To test the results for patients treated with combined photodynamic therapy (PDT) 
with vertiporﬁ  n (Visudyne, Novartis AG) and intravitreal bevacizumab for choroidal neovas-
cularization (CNV) secondary to age-related macular degeneration (AMD).
Patients and methods: This is a prospective study including 18 eyes with subfoveal or 
juxtafoveal CNV secondary to AMD. Patients were treated with intravitreal bevacizumab 
2.5 mg in the morning then PDT with vertiporﬁ  n in the evening of the same day. All patients 
were followed up for 6 months. The main outcome measures were stabilization (no change) or 
improvement of best corrected visual acuity (BCVA) with no leakage in ﬂ  uorescein angiography 
(FLA) and reduction of central retinal thickness, and retreatment rate.
Results: At the end of 6 months follow up, all cases had either stabilization or improved 
BCVA. Fifteen eyes (80%) showed improved BCVA. The overall mean improvement in BCVA 
(n = 18) was 2.17 lines. Fifteen eyes (80%) required single combined treatment. Only 3 eyes 
(20%) required retreatment with the same protocol. No systemic or ocular complications were 
reported.
Conclusion: Combined intravitreal bevacizumab and PDT as a treatment of CNV secondary to 
AMD either for predominantly classic or occult subtypes has a positive therapeutic effect with 
stabilization or improvement of ﬁ  nal BCVA and also might reduce the need for retreatment 
compared with literature retreatment rates of either modality alone.
Summary: Eighteen patients receiving combined therapy with PDT and intravitreal bevaci-
zumab for CNV secondary to AMD, showed not only signiﬁ  cant visual improvement but also 
reduction in the frequency of retreatment when compared to the results of monotherapy with 
each modality.
Keywords: intravitreal bevacizumab, photodynamic therapy, vertiporﬁ  n, choroidal neovascu-
larization, age-related macular degeneration
Background
The beneﬁ  cial effect of photodynamic therapy (PDT) treatment for choroidal neovas-
cularization (CNV) secondary to age-related macular degeneration (AMD) has been 
addressed in several reports (TAP 1999). Other reports also addressed the beneﬁ  cial 
effect of combined PDT and Triamcinolone acetonide in CNV secondary to AMD 
(Rechtman 2004; Spaide 2005). Recent reports addressed the beneﬁ  cial effect of “off-
label use of bevacizumab”, an antibody against vascular endothelial growth factor 
(VEGF), in treatment of CNV (Rosenﬁ  eld 2005; Avery 2006).
Anti-VEGF agents have been used as a primary treatment for neovascular AMD 
(Gragoudas 2004; Rosenﬁ  eld 2005; Avery 2006). This modality has gained wide 
spread use after the encouraging results of improvement of visual acuity in several Clinical Ophthalmology 2008:2(1) 160
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published reports in spite the patient may receive injection 
every 4–6 weeks requiring frequent follow-up visits with 
increasing risks of endophthalmitis and also no guarantee of 
permanent cure of the CNV and its neovascular complex even 
with repeated injection (Gragoudas et al 2004; Gruewald 
et al 2006). Prevention of visual loss and improvement of 
the mean best corrected visual acuity (BCVA) were reported 
in 2 recent, double-blind, randomized, controlled studies 
carried out with ranibizumab (Rosenfeld et al 2006; Brown 
et al 2006). Even after the approval by the Food and Drug 
Administration of ranibizumab for the treatment of CNV due 
to AMD (in June 2006), bevacizumab is still used today in 
this off-label indication because its cost is considerably lower 
than that of ranibizumab (Rosenfeld 2006).
Combined treatment of bevacizumab (anti-VEGF mono-
clonal antibody) with PDT may have a synergistic effect that 
could reduce the need for retreatment. The VEGF inhibition 
in combined treatment not only will reduce the inﬂ  ammation 
of the neovascularization but it will also limit the induced 
edema after the laser while allowing for closure of the neo-
vascular complex. PDT itself will eradicate the accessory 
support cells that were not targeted by the VEGF inhibitor 
(Dhalla et al 2006; Spaide 2006).
Methods
We constructed a prospective study of 18 CNVs, of 18 
patients secondary to AMD treated by combined intravit-
real injection of bevacizumab and PDT with vertiporﬁ  n 
(Visudyne, Novartis AG). All patients completed follow 
up for 6 months after treatment. Inclusion criteria were as 
follows: only AMD patients with either subfoveal or jux-
tafoveal CNV and either predominantly classic or occult 
types were included. Lesion size was less than 5400 μm. 
Only patients with no previous treatment were included in 
the study. Exclusion criteria included patients with CNV 
under 55 years old, minimally classic membranes, cases that 
had been previously treated with any treatment modality, 
and base line intraocular pressure 21 mmHg. The study 
was approved by the ethics committee of the eye clinic. The 
off-label use of bevacizumab as well as its potential risks 
and beneﬁ  ts were discussed with each subject. All patients 
signed written informed consent. The treatment protocol is 
to inject 2.5 mg of bevacizumab in the vitreous of the treated 
eye under complete sterile condition in operating theater (in 
the morning) followed by PDT treatment in the evening of 
the same day. Pretreatment complete ophthalmic examina-
tion including BCVA, biomicroscopic fundus examination, 
and pretreatment ﬂ  uorescein angiography (FLA) and optical 
coherence tomography (OCT) was done for all patients. All 
patients were examined at one day after treatment, at one 
week, at one month, and then monthly thereafter. FLA and 
OCT were performed twice; after 3 months and at the end 
of 6 months. The main outcome measures were stabilization 
(no change) or improvement of BCVA with no leakage in 
FLA and reduction of central retinal thickness (CRT), and 
retreatment rate as well as recording systemic and ocular 
complications. Retreatment was considered when there is 
persistent subretinal ﬂ  uid according to OCT and persistent 
leakage on FLA. Retreatment was done according to the 
same combined protocol and no retreatment was done before 
3 months after the initial therapy.
Bevacizumab injection
2.5 mg in 0.1 mL bevacizumab (Avastin, Genentech, San 
Francisco, CA) was injected intravitreal under complete 
sterile preparation in the operating theater in the usual 
sterile fashion (Aiello et al 2004) using topical anesthesia. 
Prophylactic topical antibiotic (gatiﬂ  oxacine) was given for 
2 days post-injection.
PDT
PDT (Visudyne, Novartis AG, Buelach, Switzerland) was 
performed as described previously by the TAP Study Group 
(1999).
Statistical analysis
Visual acuity was measured using Snellen’s chart and was 
converted to Log MAR for calculation of the means. Values 
were expressed as mean ± standard deviation. Lines of vision 
lost or gained were calculated as Snellen’s lines of vision (via 
Log MAR). Student’s t-test was used to compare visual acuity 
changes. p  0.05 was considered statistically signiﬁ  cant.
Results
Eighteen eyes in 18 consecutive patients were included 
in this study. All the patient characteristics are listed in 
Table 1. The study includes 10 male and 8 females. The age 
of patients ranged from 62 to 82 years with a mean of 72.8 
± 6.5 years.
The CNV lesion size, among all lesion subtypes, ranged 
from 850 μm to 3000 μm with a mean of 2033 ± 597.3 μm. 
Ten membranes were predominantly classic type with a mean 
lesion size of 1900 μm wherein the classic CNV represents 
more than 50% of the lesion size. The other 8 had occult 
leakage pattern in FLA with a mean lesion size of 2200 μm. 
As regards the lesion site, subfoveal lesions (n = 11) had Clinical Ophthalmology 2008:2(1) 161
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a mean lesion size of 2181 μm and while juxtafoveal lesions 
(n = 7) had a mean lesion size of 1800 μm.
All the patients (n = 18) included in this study got either 
stabilization (no change) or improvement of BCVA at the 
end of follow up period, both associated with no recurrent 
leakage in FLA and reduction of the pretreatment CRT by 
OCT due to absorption of pretreatment subretinal ﬂ  uid (SRF) 
(Figures 1 and 2). The overall mean improvement in BCVA 
was 2.17 lines (p = 0.004, paired samples t test). Fifteen 
eyes (80%) showed improved BCVA by the end of follow 
up period while 3 eyes (20%) showed stabilization; all the 3 
were of large lesion size as shown in Table 1.
Only 3 eyes (20%) required retreatment with the same 
protocol after 3 months from the initial treatment. No more 
cases required treatment at 6 months. Average retreatment 
rate was 1.17 ± 0.38.
Figure 1 (a) and (a-1) Pretreatment fundus photo and pretreatment FLA, late phase, showing ﬁ  lling of predominantly classic CNV occupying more than 50% of the lesion. 
Pretreatment BCVA = 20/400. (b) and (b-1) Post-treatment fundus photo and FLA, late phase, at 6 months showing closure of the CNV with only late leakage at its upper 
temporal edge (BCVA = 20/150). (c) Pretreatment OCT showing CNV with CRT = 558 μm. (c-1) OCT, 6 months post-treatment showing absorption of most of subretinal 
ﬂ  uid and reduction of CRT to 248 μm. However, fovea did not return completely to normal conﬁ  guration.
Abbreviations: BCVA, best corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; FLA, ﬂ  uorescein angiography; OCT, optical coherence 
tomography.Clinical Ophthalmology 2008:2(1) 163
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For the predominantly classic membranes (n = 10), 
Mean improvement in BCVA was 2.5 lines (p = 0.014, 
paired samples t test), 2 eyes (20%) showed stabilization 
and 8 eyes (80%) showed improved BCVA by the end of 
follow up period and only 2 eyes (20%) required retreat-
ment with the same protocol after 3 months from the initial 
treatment.
One membrane of the occult type (n = 8) (12.5%) showed 
stabilization and the rest 7 membranes (87.5%) showed visual 
improvement by the end of follow up period. The mean 
improvement in BCVA was 1.92 lines. (p = 0.005, paired 
samples t test) One eye (12.5%) required another treatment 
according to the original protocol, 3 months after the ﬁ  rst 
treatment. There was no signiﬁ  cant difference between 
predominantly classic and occult subtypes concerning the 
visual improvement. (p = 0.853)
As regards the subfoveal location (n = 11), mean improve-
ment in BCVA was 2.75 lines (p = 0.006, paired samples 
t test). Two eyes (18.2%) showed stabilization and 9 eyes 
(81.8%) showed visual improvement. Two eyes (18.2%) 
Figure 2 (a) Pretreatment fundus photo showing juxtafoveal CNV with subretinal hemorrhage occupying about 50% of the lesion (BCVA = 20/400). (a-1) Post-treatment 
fundus photo at 6 months. Note regression of the membrane and absorption of most subretinal blood (BCVA = 20/40). (b) Pretreatment FLA, showing active CNV. (b-1) 
Post-treatment FLA showing CNV staining with no leakage. (c) Pretreatment OCT showing the CNV with ﬂ  uid in the subretinal space (CRT = 800 μm). (d) OCT 6 months 
post-treatment with almost normal foveal conﬁ  guration (CRT = 280 μm).
Abbreviations: BCVA, best corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; FLA, ﬂ  uorescein angiography; OCT, optical coherence 
tomography.Clinical Ophthalmology 2008:2(1) 164
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required another treatment also after 3 months from the 
initial treatment. As regard the juxtafoveal location (n = 7), 
mean improvement in BCVA was 2.33 lines (p  0.1, 
paired samples t test). One eye (14.3%) showed stabilization 
and 6 eyes (85.7%) showed visual improvement. One eye 
(14.3%) required another treatment in the course of follow 
up. There was no signiﬁ  cant difference between subfoveal 
and juxtafoveal subtypes concerning the visual improvement 
( p = 0.856). The characteristics of different CNV subtypes 
are shown in Table 2.
Pretreatment visual acuity ranged from 20/80 to 20/400 
and the post treatment visual acuity ranged from 20/40 to 
20/400, the maximum visual gain was observed in one eye 
that improved from 20/400 to 20/40 after treatment and this 
membrane was relatively small (950 μm), and of the predomi-
nantly classic sub type with juxtafoveal location.
As regards the pretreatment central retinal thickness 
(CRT) by OCT it ranged from 400 to 850 μm with a mean 
of 590.3 ± 149.5 μm that signiﬁ  cantly improved at the end 
of follow up period to a mean of 267.5 ± 45.3 μm with range 
of 210–400 μm (p  0.001, paired samples t test).
There were no complications of treatment in this study 
group including endophthalmitis, ocular hypertension, uve-
itis, or any other systemic complications.
Discussion
According to this study there is very obvious beneﬁ  cial effect 
of combined bevacizumab injection and PDT for the treat-
ment of CNV secondary to AMD. It helps not only to stabilize 
but also to improve vision usually lost by this disease entity. 
Mean improvement in the post treatment visual acuity in our 
study (2.17 lines) is almost similar to the previously described 
newly treated patient who received monthly bevacizumab as 
a monotherapy (Miller 2005; Avery et al 2006).
Despite the demonstrated efﬁ  cacy, a substantial propor-
tion of eyes still developed moderate to severe visual loss 
after PDT. Our results are superior to the results of PDT alone 
where patients had loss of vision with an average of 2.2 lines 
in the Treatment of Age Related Macular Degeneration with 
PDT study (TAP 1999). In the VIP study (2001), average 
visual loss was 3.1 lines. Moreover, 50% of patients with 
occult CNV in AMD treated with PDT developed visual 
loss of 3 or more lines after 1 year as demonstrated in the 
VIP study (2001).
This gradual decline of vision in the course of therapy 
may be limited with the use of triamcinolone in conjunction 
with PDT. Nonrandomized studies by Spaide and colleagues 
(2003, 2005) and Rechtman and colleagues (2004), showed 
that after 6 to 12 months follow up, combined PDT/triam-
cinolone acetonide treatment of CNV due to AMD resulted 
in better outcome than PDT alone. The frequency of PDT 
is reduced with a certain degree of visual stabilization. The 
effect of triamcinolone is due to its anti-inﬂ  ammatory and 
anti-angiogenic effect (Danis et al 1996; Ciulla et al 2001), 
as well as the reduction of choriocapillary damage after PDT 
(Chan et al 2006). However, the improvement of visual acuity 
seems to be limited (Spaide et al 2005; Chan et al 2006) in 
addition to several complications like secondary glaucoma 
and cataract progression that were encountered with its use 
(Junas et al 2003; Gillies et al 2004).
The use of anti VEGF is getting popularity as a primary 
treatment for wet AMD. This treatment has demonstrated 
improvement of vision. However, patients treated with anti-
VEGF agent often receive intravitreal injections on regular 
4–6 weeks interval with increasing potential risk of ocular 
complications (Rosenﬁ  eld et al 2005; Avery et al 2006). 
Recent studies showed ranibizumab, an antibody fragment 
that inhibits VEGF, to be an effective treatment with visual 
improvement for exudative AMD but those patients still 
require multiple periodic injections (Heier et al 2006). The 
visual improvement in our study matches the results of 
Dhalla and colleagues (2006), who reported 80% stabiliza-
tion and 67% improvement of vision with average 2.04 lines 
after 7 months following combined PDT and intravitreal 
Table 2 Choroidal neovascularization subtype characteristics
Lesion  Mean lesion  Patients with  Patient with  Retreatment rate  p value between
subtype size  (μm) stabilization  visual  gaining    subgroups†
PC (10)  1,900  20%  80%  20%  p = 0.853
O (8)  2,200  12.5%  87%  12.5% 
SF (11)  2,181  18.18%  81.8%  18.18%  p = 0.856
JF (7)  1,800  14.28%  85.7%  14.28% 
Abbreviations: PC, predominantly classic; O, occult; SF, subfoveal; JF, juxtafoveal.
Notes: †The difference in visual improvement between different subgroups was statistically insigniﬁ  cant (Student’s t-test for unpaired data).Clinical Ophthalmology 2008:2(1) 165
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bevacizumab. In our study, the visual positive effect involved 
all subtypes including subfoveal and juxtafoveal, classic and 
occult. This also matches the results of Dhalla and colleagues 
(2006). Eyes with subfoveal as well as classic CNV showed 
the greatest mean visual improvement (2.75, 2.5 lines). The 
TAP study (1999) also reported a better response of classic 
lesions to PDT. The visual improvement was statistically 
insigniﬁ  cant only in the juxtafoveal subgroup. This might be 
due to the fact that lesion does not involve the center of the 
fovea, which is affected only with subretinal ﬂ  uid.
The visual improvement seen in our study as well as 
Dhalla and colleagues (2006) study is possibly due to the 
bevacizumab effect. This is supported by the ﬁ  ndings of 
Lazic and Gabric (2007), in a randomized clinical trial, who 
reported signiﬁ  cant visual improvement after 3 months in 
cases treated with bevacizumab alone as well as cases treated 
with combined bevacizumab and PDT and slight worsening 
in cases treated with PDT alone.
Another beneﬁ  cial effect of combined therapy is the 
reduction of treatment frequency. For patients treated 
with PDT alone in the TAP study (1999), the need for 
retreatment at three months is 90.8% and slightly less at 
month 6 and required an average of 3.3 retreatments in the 
ﬁ  rst year. Patients treated with anti-VEGF agents require 
intravitreal injections every 4 to 6 weeks (Gragoudas 2004; 
Miller 2005)
In our study we reported a retreatment rate of 20% of 
the whole case series after 6 months. Dhalla and colleagues 
(2006) reported a retreatment rate of 37% in 7 months 
using the same combined therapy. The frequency of PDT 
was found to be signiﬁ  cantly reduced when combined with 
triamcinolone intravitreal injection with retreatment rate of 
1.24 (Spaide 2005). Our results as well as those of Dhalla 
and colleagues (2006) showed that combined therapy reduces 
the frequency of both PDT and intravitreal injection thus 
reducing the economic cost of treatment and reduces the risk 
of complications of intravitreal injection as endophthalmitis 
and retinal detachment.
One of the reasons for less favorable outcome in treat-
ing CNV secondary to AMD with PDT might be because of 
collateral damage of adjacent structures as choriocapillary 
hypo perfusion and retinal pigment epithelium atrophy after 
PDT (Flower et al 2001; Moshfeghi et al 2003; Wachtlin et al 
2003). The associated damage results in retinal edema and 
release of angiogenesis factors such as VEGF (Rogers et al 
2002; Schmidt-Erfurth et al 2003).
Meanwhile, the neovascular beds that have mature 
smooth muscle and pericyte support don’t regress completely 
with VEGF inhibition and may lay dormant only as long as 
VEGF is suppressed (Bergers et al 2003; Erber et al 2004; 
Dhalla et al 2006), hence the need for frequent injections. So, 
nonthermal laser may be necessary to disrupt the anatomical 
component of CNV that do not respond to VEGF inhibition 
(Dhalla et al 2006), and anti-VEGF might be necessary to 
reduce the damage of the VEGF released by PDT. This might 
give justiﬁ  cation and also an explanation for the efﬁ  cacy 
of this combined treatment. Minimally classic and occult 
membranes are located more deeply than classical mem-
branes and their exposure to light is reduced by surrounding 
factors. Because light activation of the drugs present in these 
membranes is less effective, this could explain the limited 
beneﬁ  ts of PDT in minimally classic and occult CNV (Lazic 
and Gabric 2007). A way to overcome this difﬁ  culty is to 
use intravitreal therapeutic agents that, by diffusion, a have 
better chance of reaching the deepest lesions; another reason 
for using combined therapy.
In our series, both treatments were given in the same day 
with the rationale of reducing the damage resulting from 
VEGF release after PDT. Intravitreal injection was given 
ﬁ  rst to avoid exposure to strong light during the injection 
after having PDT. However, Dhalla and colleagues (2006), 
reported giving either treatment within 14 days interval 
with results are very close to ours. Lazic and Gabric (2007) 
reported that bevacizumab was given within one hour after 
PDT also with visual improvement. The optimal timing of 
bevacizumab injection in relation to the PDT procedure, 
therefore, warrants further investigation.
With the use of bevacizumab neither cataract nor glau-
coma was encountered in our study which makes it safer 
when compared with triamcinolone.
Our study with combined treatment of bevacizumab and 
PDT demonstrated that this treatment seems to be effective 
for treatment of CNV secondary to AMD whatever the type 
of this membrane (occult, classic and subfoveal, juxtafoveal). 
In spite of the small sample of the treated eyes but the ﬁ  nd-
ings seem to be encouraging. This observation matches the 
results of Dhalla and colleagues (2006). Lazic and Gabric 
(2007) reported a similar improvement in both occult and 
minimally classic CNV due to AMD at 3 months.
In summary, combined intravitreal bevacizumab and 
PDT as a treatment of CNV secondary to AMD either for 
predominantly classic or occult subtypes has a positive 
therapeutic effect with stabilization or improvement of 
ﬁ  nal BCVA and also might reduce the need for retreat-
ment compared to literature retreatment rates of either 
modality alone.Clinical Ophthalmology 2008:2(1) 166
Kabeel et al
The main limitations in our study were the lack of ran-
domization as well as small number of cases. In view of the 
encouraging results, further randomized controlled studies 
may be justiﬁ  ed to determine the role of this combined 
therapy for neovascular AMD.
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